Affiliation:
1. Department of Pharmacy, Integral University, Lucknow,
India
Abstract
AbstractEvery year, the World Health Organization reports 500,000 new cases of
drug-resistant tuberculosis (TB), which poses a serious global danger. The
increased number of XDR-TB and MDR-TB cases reported worldwide necessitates the
use of new therapeutic approaches. The main issues with the antitubercular
medications now in use for the treatment of multidrug-resistant tuberculosis are
their poor side effect profile, reduced efficacy, and antimicrobial resistance.
One possible remedy for these problems is bedaquiline. The need for better
treatment strategies is highlighted by the strong minimum inhibitory
concentrations that bedaquiline (BDQ), a novel anti-TB medicine, exhibits
against both drug-resistant and drug-susceptible TB. Bedaquiline may be able to
help with these problems. Bedaquiline is a medication that is first in its class
and has a distinct and particular mode of action. Bedaquiline is an ATP synthase
inhibitor that is specifically directed against Mycobacterium tuberculosis and
some nontuberculous mycobacteria. It is metabolized by CYP3A4. Bedaquiline
preclinical investigations revealed intralesional drug biodistribution. The
precise intralesional and multi-compartment pharmacokinetics of bedaquiline were
obtained using PET bioimaging and high-resolution autoradiography
investigations. Reduced CFU counts were observed in another investigation after
a 12-week course of therapy. Meta-analyses and systematic reviews of phase II
trials on bedaquilineʼs efficacy in treating drug-resistant tuberculosis in
patients reported higher rates of cure, better culture conversion, and lower
death rates when taken in conjunction with a background regimen. Here is a
thorough medication profile for bedaquiline to aid medical professionals in
treating individuals with tuberculosis.